Compare Oxford Lane Capital Corp (OXLC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oxford Lane Capital Corp vs 10X Genomics Inc — how do they compare? Oxford Lane Capital Corp trades at $8.51 (market cap $835.71M), while 10X Genomics Inc trades at $82.37 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 12× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 28.15% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oxford Lane Capital Corp for 49 Days and 10X Genomics Inc for 92 Days on average.
| OXLC | TXG | |
|---|---|---|
Market Cap | $835.71M | $10.07B |
Volume | 1,125,263 | 5,657,286 |
Sector | Financials | Health |
52-Week High | $16.74 | $97.74 |
52-Week Low | $8.15 | $11.48 |
Typical Hold Time | 49 Days | 92 Days |
Enterprise Value | $1.23B | $9.59B |
Dividend Yield | 28.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $8.46, down 2.53% on the day, with a bearish technical outlook indicated by moving averages and oscillators. Recent earnings misses and a sharp decline in 2026 revenue and net income highlight fundamental challenges, though the stock trades below book value. The company maintains a regular dividend payout, but negative cash flow from operations and high interest expenses pose sustainability concerns.
The outlook is cautious due to deteriorating profitability and bearish sentiment, though deep valuation discounts may attract contrarian investors. Key risks include earnings volatility, dividend coverage, and market sentiment shifts. Analyst consensus is mixed, with half recommending buy but technicals signaling sell.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
